Editas Medicine

Editas Medicine

Yahoo Finance • 29 days ago

CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?

Gene-editing technology has moved from science fiction to clinical reality, forcing investors to choose between commercial leaders and early-stage innovators. Deciding between CRISPR Therapeutics AG(NASDAQ:CRSP) and Editas Medicine(NASDAQ:... Full story

Yahoo Finance • last month

Editas Medicine Announces Proposed Public Offering

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced that it has commenced an underwritten pu... Full story

Yahoo Finance • 2 months ago

Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting

CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical data supporting the continued adv... Full story

Yahoo Finance • 9 months ago

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

CAMBRIDGE, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today reported in vivo preclinical proof-of-concept data for EDIT-401, an experimental, potential best-in-class,... Full story

Yahoo Finance • 10 months ago

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into second quarter of 2027 Company-sponsor... Full story

Yahoo Finance • 10 months ago

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will host a webinar... Full story

Yahoo Finance • 10 months ago

Vanguard Consumer Staples Breaks Below 200-Day Moving Average - Notable for VDC

In trading on Tuesday, shares of the Vanguard Consumer Staples ETF (Symbol: VDC) crossed below their 200 day moving average of $218.17, changing hands as low as $217.61 per share. Vanguard Consumer Staples shares are currently trading off... Full story

Yahoo Finance • 10 months ago

H.C. Wainwright raises Editas Medicine stock price target to $5 on pipeline progress

Investing.com - H.C. Wainwright raised its price target on Editas Medicine (NASDAQ:EDIT) to $5.00 from $3.00 on Friday, while maintaining a Buy rating on the gene editing company’s stock. The upgrade comes as Editas shares have surged over... Full story

Yahoo Finance • 11 months ago

Top movers in Wednesday's session

Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session. [topmovers] TOP GAINERS TICKER CHANGE COMMENT WBTN [https://www.ch... Full story

Yahoo Finance • 11 months ago

Wednesday's session: gap up and gap down stocks

The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session. [gap] GAP UP STOCKS TICKER CHANGE COMMENT BSLK [https://www.chartmill.com/stock/quote/BS... Full story

Yahoo Finance • 11 months ago

Editas Medicine earnings missed by $0.23, revenue topped estimates

Investing.com - Editas Medicine (NASDAQ: EDIT) reported second quarter EPS of $-0.63, $0.23 worse than the analyst estimate of $-0.40. Revenue for the quarter came in at $3.58M versus the consensus estimate of $2.15M. Editas Medicine’s... Full story

Yahoo Finance • 11 months ago

Editas Medicine Inc (NASDAQ:EDIT) Reports Mixed Q2 2025 Earnings: Revenue Beat but Wider Loss

Editas Medicine Inc (NASDAQ:EDIT [https://www.chartmill.com/stock/quote/EDIT]) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The gene-editing company posted revenue of $3... Full story

Yahoo Finance • 11 months ago

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program as part of collaboration with Bristol My... Full story

Yahoo Finance • 11 months ago

Can This Beaten-Down Stock Bounce Back?

Key Points Editas Medicine's shares are up in 2025, but the stock has lagged the market in recent years. The struggling biotech decided to shift its strategy after encountering some clinical setbacks. Still, it is miles away from regulato... Full story

Yahoo Finance • 12 months ago

Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data

Editas Medicine, Inc. (NASDAQ:EDIT) ranks among the best CRISPR stocks to buy. At the European Hematology Association 2025 Congress on June 12, Editas Medicine, Inc. (NASDAQ:EDIT) revealed new in vivo data showing notable progress in gene... Full story

Yahoo Finance • last year

Lilly-Verve deal sends gene editing stocks higher

[Illustration of DNA strand with molecular scissors] Love Employee/iStock via Getty Images Biotech firms focused on gene therapies traded higher after Eli Lilly (NYSE:LLY [https://seekingalpha.com/symbol/LLY]) agreed to acquire Boston-bas... Full story

Yahoo Finance • last year

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

Key Points The clinical-stage biotech is developing gene-editing CRISPR technology. Editas has reported encouraging testing results in laboratory animals. Still, the stock remains speculative amid uncertainties and challenges. 10 stocks w... Full story

Yahoo Finance • last year

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in... Full story

Yahoo Finance • last year

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025... Full story

Yahoo Finance • last year

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT)... Full story